Here is the design of a clinical trial:

Official Title: Study of Pd-1 Antibody in Combination with Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Included conditions:
- Uterine Cervical Neoplasm
- Uterine Cervical Cancer
- Cervical Cancer

Study Armgroups:
- {'label': 'Study group', 'type': 'EXPERIMENTAL', 'description': 'Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.', 'interventionNames': ['Drug: Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)']}

Interventions:
- {'type': 'DRUG', 'name': 'Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)', 'description': 'PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W', 'armGroupLabels': ['Study group']}

Primary Outcomes:
- {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of the participants in the ITT population who have a Complete Response or Partial Response. The ORR will be assessed by a blind independent central reviewer per RECIST 1.1', 'timeFrame': '3 months'}

Please estimate the sample size based on the assumption: 
One-sided binomial test, type I error rate of 0.05, power of 91.4%, estimated dropout rate of 15%.
Sample size calculation
          The clinical response rate in patients with LACC after NACT is approximately 70%.20 21 With a one-sided binomial test at an overall type I error rate of a=0.05, a sample size of 69 patients is needed to maintain 91.4% power under the hypothesis that the overall response rate of neoadjuvant immunotherapy is expected to increase to 85%. Eighty-two patients are included in the study, with an estimated dropout rate of 15%.